TITLE

Hard Work, Thorough Analysis, and Planning Raise Quality Assurance from 483 Ashes

AUTHOR(S)
Fellows, Lindon
PUB. DATE
August 2003
SOURCE
Pharmaceutical Technology;Aug2003 Supplement, Vol. 27 Issue 8, p90
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the DSM Pharmaceuticals Inc.'s comprehensive plan to improve manufacturing processes and change the employee culture. Overview on the company's compliance problem in its acquired contract manufacturing facility; Implementation of the program, QUICK Start to Excellence; Corporate policy.
ACCESSION #
10603783

 

Related Articles

  • DSM Pharmaceuticals To Double Sterile Manufacturing Capacity. Russel, Ronelle // Pharmaceutical Technology;Feb2003, Vol. 27 Issue 2, p20 

    Reports on Greenville, North Carolina-based drug company DSM Pharmaceuticals' plans to expand its sterile manufacturing capacity. Addition of five freeze dryers and a filling line to its manufacturing site in Greenville; Manufacturing capacity of the facility upon the positioning of freeze...

  • Contract Services' Crystal Ball. Miller, Jim // BioPharm International;Feb2003, Vol. 16 Issue 2, p22 

    Reports developments in the pharmaceutical industry as of February 2003 in the U.S. Acquisition of Magellan Laboratories by Cardinal Health; Use of electronic data capture in the clinical trials of Novartis; Plans inspection conducted by Food and Drug Administration for DSM Pharmaceuticals Inc.

  • CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.  // Worldwide Biotech;May2005, Vol. 17 Issue 5, p3 

    Reports on a PER. C6 cell line research license agreement signed by DSM Biologics with Japanese pharmaceutical company Mitsubishi Pharma Corp. in 2005. Benefit of the license agreement for Mitsubishi; Terms of the contract; Information on DSM Biologics.

  • Capacity Worries Fade for Biomanufacturing. Miller, Jim // Pharmaceutical Technology;Jul2003, Vol. 27 Issue 7, p82 

    Reports on the prospective increase in biomanufacturing capacity, with the announcement of biomanufacturing investments by several companies. Construction of a commercial-scale biomanufacturing facility in Montreal, Quebec, by DSM; Diosynth's addition of cell-culture capacity; Microbial...

  • INDUSTRY pipeline.  // Pharmaceutical Technology;Jul2003, Vol. 27 Issue 7, p83 

    Presents a sampling of pharmaceutical products and services. Contract manufacturing and development services from DSM Pharmaceuticals; Peristaltic pumps from Watson-Marlow Bredel; Silicone labeling system from AdvantaPure; Forma 8600 Series-86C upright freezers from Thermo Electron Corp.

  • News and Views.  // Pharmaceutical Technology;May2006, Vol. 30 Issue 5, p96 

    The article offers developments related to pharmacology. DSM Biologics and AC Immune SA have agreed that DSM will develop and manufacture AC immune's monoclonial antibody for Alzheimer's disease. AdvantaPure is currently an employee owned under an employee stock ownership plan. Jost Chemical Co....

  • Royal DSM N.V. SWOT Analysis.  // DSM N.V. SWOT Analysis;9/ 1/2014, p1 

    A business analysis of nutritional and pharmaceutical products manufacturer Koninklijke DSM or Royal DSM is provided, focusing on the strengths, weaknesses, opportunities and threats (SWOT) faced by the company. Strengths include benefits derived from its diversified business nature. Weaknesses...

  • Pharma CAPSULES.  // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p106 

    The article offers news briefs related to the pharmaceutical industry. A new facility called PERCIVIA PER.C6 Development Center was opened by biotechnology company Crucell NV and technology partner DSM Biologics. A high-speed packaging line is planned by contract manufacturer Surefil LLC to...

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics